Back to Journals » OncoTargets and Therapy » Volume 9

Original Research

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

       
Total article views   HTML views PDF downloads Totals
6,051 Dovepress* 5,616+ 1,166 6,782
PubMed Central* 435 232 667
Totals 6,051 1,398 7,449
*Since 30 June 2016
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
3 0 0 0 1 2

View citations on PubMed Central and Google Scholar